Estudo randomizado | Duração da terapia adjuvante com inibidor de aromatase no câncer de mama pós-menopausa.
2 Ago, 2021 | 18:05h
Comentário no Twitter
In postmenopausal women with hormone-receptor-positive breast cancer who had 5 yrs of AI, extending adjuvant endocrine therapy by 5 years provides no benefit over a 2-year extension but is associated with a greater risk of bone fracturehttps://t.co/YDxeQVu8B9
— K Pavithran (@drkpavithran) July 29, 2021